General News

removal-robertMelbourne-based Robert has lived with type 1 diabetes (T1D) for nearly fifty years, after diagnosis at the age of 18. A self-described travel enthusiast, the retired bus driver and father of three daughters and grandfather of seven, can add another role to his resume – clinical trial participant.

He has put his hand up to participate in the multi-national REMOVAL trial, which is testing whether metformin (a glucose-lowering medication) can help to protect cardiovascular health in people with T1D. See more about REMOVAL below.

Robert remembers the old days of “using glass insulin syringes for injections, practicing injections on oranges, giving myself two injections a day and doing frequent urine tests with Clinistix”, and can see the real impact that diabetes research can have when he compares changes in diabetes treatments from then to now.

He estimates that he’s done at least 12,500 urine tests, 45,500 blood glucose tests, and over 1040 insulin pump site changes in his life. Living with T1D is now part of his everyday routine, but he still wants to contribute to a future free of T1D and knows that participating in a clinical trial will help.

Robert says “a cure would be awesome, not so much for me, but for young people it would be fantastic. It would mean so much freedom. Freedom from monitoring, having a normally functioning body and not having to worry about or deal with diabetes complications”.

To join Robert and become a clinical trial participant, visit the CRN website for more information about Australian clinical trials. 


More about REMOVAL

removalREMOVAL is the first study to test the success of metformin medication in maintaining cardiovascular health for adults with T1D, and results are likely to impact how people with T1D are treated in the future. While it is a worldwide study, there is an ‘Australia only’ part which studies heart health and blood of participants and the response to metformin.

Principal Investigator Dr Alicia Jenkins says “Health outcomes for people living with T1D now and in the future cannot be improved without carefully conducted well-controlled medical research involving informed people with T1D. They are essential to decide if metformin is an effective, well-tolerated and cost-effective treatment to reduce the risk of cardiovascular damage for adults with T1D.”

The Australian sub-study for REMOVAL is funded by the Type 1 Diabetes Clinical Research Network, which strengthens links between researchers, people with T1D, government, and funding agencies, to faster improve the lives of people with type 1 diabetes now and into the future.

To register your interest in participating in REMOVAL, visit the CRN website.

Leave a Reply